期刊文献+

弥漫性大B细胞淋巴瘤中miR-34a、FOXP1表达的相关性及临床意义 被引量:4

Correlation and clinical significance of miR-34a and FOXP1 expression in diffuse large B-cell lymphoma
下载PDF
导出
摘要 目的研究弥漫性大B细胞淋巴瘤(DLBCL)中微小RNA(miR)-34a、叉头框蛋白P1(FOXP1)表达的相关性及临床意义。方法选择2018年2月至2019年7月期间经达州市中心医院病理确诊的DLBCL组织79例和反应性增生淋巴结组织60例,采用荧光定量PCR检测miR-34a的表达水平、western blot检测FOXP1的表达水平,分析miR-34a与FOXP1的相关性。随访并分析不同miR-34a、FOXP1表达的DLBCL患者无进展生存情况的差异。结果DLBCL组织中miR-34a的表达水平低于反应性增生淋巴结组织、FOXP1的表达水平高于反应性增生淋巴结组织,差异有统计学意义(P<0.05);DLBCL组织中miR-34a与FOXP1具有负相关关系(r=-0.528,P<0.05);与临床分期Ⅰ~Ⅱ期、LDH正常、IPI评分0~1分、GCB亚型DLBCL组织比较,临床分期Ⅲ~Ⅳ期、LDH升高、IPI评分≥2分、Nom-GCB亚型DLBCL组织中miR-34a的表达水平明显降低、FOXP1的表达水平明显升高差异有统计学意义(P<0.05);miR-34a表达水平≥中位数的DLBCL患者无进展生存时间较miR-34a表达水平<中位数的DLB CL患者延长,FOXP1表达水平≥中位数的DLB CL患者无进展生存时间较FOXP1表达水平<中位数的DLBCL患者缩短。结论miR-34a低表达、FOXP1高表达与DLBCL的病理进展及预后恶化有关。 Objective To study the correlation and clinical significance of microRNA(miR)⁃34a and forkhead box protein P1(FOXP1)expression in diffuse large B⁃cell lymphoma(DLBCL).Methods From February 2018 to July 2019,79 cases of DLBCL and 60 cases of reactive hyperplasia lymph node tissues confirmed by pathology in our hospital were selected.The expression level of miR⁃34a was detected by fluorescence quantitative PCR,and the expression level of FOXP1 was detected by Western blot.The correlation between miR⁃34a and FOXP1 was analyzed.The progression free survival of DLBCL patients with different expression of miR⁃34a and FOXP1 was followed up and analyzed.Result The expression level of miR⁃34a in DLBCL tissue was lower than that in reactive proliferative lymph node tissue,and the expression level of FOXP1 was higher than that in reactive proliferative lymph node tissue(P<0.05),and there was a negative correlation between miR⁃34a and FOXP1 in DLBCL tissue;compared with clinical stageⅠ~Ⅱ,normal LDH,IPI score 0⁃1,GCB subtype DLBCL tissue,the expression level of miR⁃34a significantly decreased and the expression level of FOXP1 significantly increased in clinical stageⅢ~Ⅳ,increased LDH,IPI score≥2,non GCB subtype DLBCL tissue.The progression free survival time of DLBCL patients with miR⁃34a expression level≥median was longer than that of DLBCL patients with miR⁃34a expression level<median,and the progression free survival time of DLBCL patients with FOXP1 expression level≥median was shorter than that of DLBCL patients with FOXP1 expression level<median.Conclusion Low expression of miR⁃34a and high expression of FOXP1 are associated with the occurrence,pathological progression and prognosis of DLBCL.
作者 陈思言 杨丽华 张伶莉 董事 李亚琼 龚吉昌 罗河 魏中华 李先莉 CHEN Siyan;YANG Lihua;ZHANG Lingli;DONG Shi;LI Yaqiong;GONG Jichang;LUO He;WEI Zhonghua;LI Xianli(Department of Hematology,Dazhou Central Hospital,Dazhou,Sichuan,China,635099;Department of Laboratory,Dazhou Central Hospital,Dazhou,Sichuan,China,635099)
出处 《分子诊断与治疗杂志》 2022年第1期40-44,共5页 Journal of Molecular Diagnostics and Therapy
基金 达州市级科技计划(指导性)项目(MDS18203)。
关键词 弥漫性大B细胞淋巴瘤 微小RNA-34a 叉头框蛋白P1 Diffuse large B-cell lymphoma MicroRNA-34a Forkhead box protein P1
  • 相关文献

参考文献5

二级参考文献33

  • 1Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 2Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 3Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 4Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 5Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 6Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 7Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.
  • 8Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127.
  • 9Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin' s lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, Suppl 2:ii67-69.
  • 10NCCN Guidelines. Non-Hodgkin' s Lymphomas, version 2.2012.

共引文献260

同被引文献37

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部